We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia (COUGH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01217879
Recruitment Status : Completed
First Posted : October 8, 2010
Last Update Posted : November 16, 2012
Sponsor:
Information provided by:
Bayer

Brief Summary:
In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.

Condition or disease Intervention/treatment
Hypertension Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

Study Type : Observational
Actual Enrollment : 980 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cough Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop Previous ACE-i Treatment Due to Cough
Study Start Date : January 2010
Primary Completion Date : September 2010
Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough
Drug Information available for: Telmisartan
U.S. FDA Resources

Group/Cohort Intervention/treatment
Group 1 Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment



Primary Outcome Measures :
  1. Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough [ Time Frame: 4 months after initiation ]

Secondary Outcome Measures :
  1. Number of Participants with Adverse Events among patients, who had to stop their previous ACE-I treatment due to cough [ Time Frame: 4 months after initiation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic hypertensive patients with cough caused by the ACE-I regardless any other factors.
Criteria

Inclusion Criteria:

  • Hypertension
  • Age > 18
  • ACE-I related cough

Exclusion Criteria:

  • Current treatment with telmisartan
  • Cholestatic disorders and severe hepatic failure
  • Allergy to telmisartan
  • Pregnancy and lactation period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01217879


Locations
Slovakia
Many Locations, Slovakia
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Medical Director, Bayer s. r. o, Obchodna 2, 811 06 Bratislava
ClinicalTrials.gov Identifier: NCT01217879     History of Changes
Other Study ID Numbers: 15379
KL0910SK ( Other Identifier: Company internal )
14881 - KL0910PL ( Other Identifier: Company internal )
GM.2009-04-06.0017 ( Other Identifier: Company internal )
First Posted: October 8, 2010    Key Record Dates
Last Update Posted: November 16, 2012
Last Verified: November 2012

Keywords provided by Bayer:
Cough
Telmisartan
Bradykinin
Tolerability

Additional relevant MeSH terms:
Cough
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Telmisartan
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action